Trial Profile

Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Adenocarcinoma; Bronchiolo-alveolar adenocarcinoma; Large cell carcinoma; Neuroendocrine carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms I-SABR

22 Jun 2026 Planned End Date changed from 30 Jun 2026 to 30 Jun 2028.
22 Jun 2026 Planned primary completion date changed from 30 Jun 2026 to 30 Jun 2028.
23 Apr 2024 Planned End Date changed from 30 Jun 2025 to 30 Jun 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com